Nutshell Therapeutics gets FDA IND clearance for AI-found NRF2 degrader NTS231

Nutshell Therapeutics said the FDA cleared NTS231, a drug its AI platform found, to start U.S. trials aimed at tumors that lean on the NRF2 survival pathway.

HEALTH desk — NRF2 is a protein some tumors use to survive treatment, and most targeted cancer drugs do not touch it. An FDA clearance lets Nutshell start U.S. Trials of NTS231. It is not proof the drug helps patients.

What the lede says the drug is. Nutshell Therapeutics, called an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch clinical development in the United States. A molecular glue, here, is a small molecule that helps two proteins stick so the cell’s disposal machinery can destroy one of them. Allosteric means it binds somewhere other than the protein’s usual active site. Covalent means the bond is a lasting chemical link, not a grip that lets go. NRF2 is a protein some cancer cells use to survive stress, including treatment. Degrader means the drug is meant to make the cell destroy NRF2, not merely block it for a moment.

Whose first, and whose second. The wire says NTS231 is the first NRF2 degrader molecule from China and second globally to enter clinical development. First and second are the company’s words. The wire calls the NRF2 pathway a key driver of tumor survival and treatment resistance in multiple cancer types. Key driver is the company’s phrase.

How the company says it found the molecule. The discovery section says NTS231 was powered by the proprietary AI-driven allosteric drug discovery platform ALLOSTAR™, which integrates computer-aided drug design, medicinal chemistry, and experimental techniques. Computer-aided drug design means software helped propose and score molecules. Medicinal chemistry is the work of changing a molecule’s structure and testing what the change did. The wire says the team accomplished IND approval within 24 months from target nomination. Target nomination is the moment the company chose NRF2 as the thing to go after. Twenty-four months is the company’s clock. The wire’s word in that sentence is IND approval. The headline’s word is IND clearance. This desk reads both as the FDA letting the study start, not as a marketed-drug approval.

How the wire says the molecule works. NTS231 covalently binds to KEAP1 and induces the degradation of NRF2. Highly potent and selective are the company’s words for the molecule. KEAP1 is the protein that, in a healthy cell, helps mark NRF2 for disposal. In many of these tumors that partnership is broken, so NRF2 stays on. The wire says NTS231 irreversibly links to the Cys151 residue of KEAP1. Cys151 is one cysteine, a sulfur-bearing spot on KEAP1. Irreversibly means the link is not meant to come off. The wire says that link stabilizes a KEAP1 shape that favors interaction with CUL3 and the assembly of a working KEAP1–CUL3 E3-ligase complex, which drives NRF2 degradation, suppresses NRF2 signaling, and inhibits cancer cell viability. An E3 ligase is the complex that tags a protein for the cell’s shredder. Viability, here, means whether the cancer cells stay alive in the experiment.

What the preclinical section claims, and whose comparison it is. In preclinical studies, the wire says NTS231 shows non-inferior in vitro activity to VVD-130037, a clinical-stage compound under the same targeting mechanism, with superior pharmacokinetic properties. Non-inferior means not worse, on the tests they name. In vitro means in cells, not in a person. Pharmacokinetic means how the body absorbs, moves, and clears the drug. VVD-130037 is the wire’s comparator name. The wire does not say who makes it. Across multiple cell-derived xenograft and patient-derived xenograft models with NRF2, KEAP1, or CUL3 mutations, or NRF2 hyperactivation, the wire says NTS231 showed dose-dependent antitumor effect as a single agent in lung squamous cell carcinoma, lung adenocarcinoma, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. A xenograft is a human tumor grown in a mouse. Cell-derived means the tumor started from a lab cell line. Patient-derived means it started from a patient’s tumor. Dose-dependent means a higher dose did more, on the company’s curves. The wire’s short names are LUSC, LUAD, ESCC, and HNSCC.

Combinations the wire names, still preclinical. The wire says synergistic effects showed up with chemotherapy, targeted therapies, and antibody-drug conjugates. An antibody-drug conjugate is an antibody that carries a toxin to a tumor cell. Synergistic means the pair beat either drug alone, on the company’s test. In chemotherapy-resistant lung squamous models with KEAP1 and other mutations, the wire says NTS231 plus paclitaxel significantly enhanced tumor growth inhibition versus either agent alone. In a proof-of-concept cell-line model of NFE2L2-amplified lung adenocarcinoma, NTS231 plus a TROP2 antibody-drug conjugate improved efficacy and led to tumor regression, with lower expression of NRF2-regulated efflux transporters, which the wire says might sensitize tumors to the conjugate’s payload and mitigate resistance. NFE2L2 is the gene that encodes NRF2. Amplified means the cell has extra copies. An efflux transporter pumps a drug back out of the cell. Might is the wire’s word. It is not a patient result.

The animal safety line, kept off humans. In 28-day Good Laboratory Practice toxicology studies in rats and dogs, the wire says NTS231 showed a favorable safety profile and a wide safety margin. Good Laboratory Practice is a rulebook for how those animal studies are run and recorded. A safety margin is the gap between a dose that hurts and a dose you might use. Favorable and wide are the company’s words. These are rats and dogs. They are not the first human volunteers.

The patient-count sentences, and which footnote holds them. The wire says NRF2 stuck in the on position shows up in many human cancers because of changes in NFE2L2 and in the genes that regulate it, KEAP1 and CUL3. It says about 12 percent of cancer patients profiled in The Cancer Genome Atlas carry a mutation in at least one of those three genes, and that this is particularly common in more than 30 percent of lung squamous tumors and more than 20 percent of lung adenocarcinomas. It says preliminary estimates indicate over 1.5 million new cancer cases a year worldwide harbor NRF2, KEAP1, or CUL3 alterations or other aberrant NRF2 pathway activation. Preliminary is the wire’s word. Footnote 2 under that sentence is Cerami and colleagues, Cancer Discovery, 2012, the paper that introduced the cBio cancer-genomics portal. That paper is a portal, not a 2026 headcount.5 million. The 12 percent, the 30 percent, the 20 percent, and the 1.5 million are the wire’s.

Why the wire says these patients are hard to treat. It says NRF2, KEAP1, and CUL3 alterations are mutually exclusive with EGFR, ALK, ROS1, and BRAF lesions, so this group is largely ineligible for most targeted therapies. Mutually exclusive, here, means the tumor usually has one of these changes, not both. It says immunotherapy also does little, because these mutations are strongly associated with an immunologically cold tumor, which leads to resistance. Cold means few immune cells in the tumor. It says constant NRF2 activation can also confer resistance to standard chemotherapy. Those sentences are the company’s case for an unmet need.

What the about box says the company is. Nutshell Therapeutics uses artificial intelligence and allosteric drug discovery against targets it calls historically challenging and undruggable. Founded by Professor Zhang Jian, whom the wire calls a pioneer in allosteric drug discovery. The team spans artificial intelligence, medicinal chemistry, pharmacology, toxicology, and clinical development. The wire says a 1,500-square-meter research center in Shanghai. It says the company has raised tens of millions of U.S. Dollars from venture investors. Tens of millions is the wire’s phrase. It does not print a round size, a valuation, or the investors’ names. Pioneer, undruggable, and 1,500 are the about box.

An earlier Chinese-language item, not this wire’s clock. Sina Finance, 17 Sep 2026, 16:42, source line 医药观澜, says that on 10 Sep 宇道生物, which it also writes as Nutshell Therapeutic, announced FDA IND clearance for NTS231. The mechanism sentences on that page match this wire’s KEAP1 Cys151 account. The day on the Sina page is 17 Sep. The day it attributes to the company is 10 Sep. The English wire’s day is 25 Sep. This desk read the Sina page.

What the public site still shows, kept apart from the wire. The page at allonutshell.com, read 25 Sep 2026, calls the platform AlloStar™, with that capitalization, and calls the company a clinical-stage biotech. The wire spells the platform ALLOSTAR™. The site’s lead program on that page is NTS071, a p53 Y220C reactivator it says is in Phase I/II trials in the U.S. And China. NTS071 is a different molecule. The pipeline row for this filing is labeled NRF2 / NTS231, allosteric degrader, solid tumor. The paragraph in the HTML under that row describes SGR-3515, a dual Wee1/Myt1 inhibitor. That paragraph is not a description of NTS231.

What the card shows. The card is a headless crop of the Nutshell Therapeutics pipeline table at allonutshell.com. The row under p53 Y220C / NTS071 reads NRF2 / NTS231, allosteric degrader, solid tumor. It is the company’s pipeline table. It is not the company logo, the homepage swirl, a patient, or a molecule diagram. No date is printed on the card.

Plain English for the rest of the card. A Shanghai company that uses software to hunt drugs said the FDA will let it start U.S. trials of NTS231. The drug is built to stick to KEAP1 and make the cell destroy NRF2, a protein some tumors use to survive. The mouse and cell results, the comparison with VVD-130037, and the rat and dog safety line are the company’s. None of that is a result in a patient yet.